Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma
Grzegorz Przywara1,2, Oliwia Biegańska1,2, Emilia Biczak1,2
1Faculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.
Abstract:
Mucinous ovarian carcinoma (MOC) represents a rare and biologically distinct subtype of ovarian cancer, characterized by poor response to standard platinum-based chemotherapy and a unique molecular profile, including frequent KRAS mutations and HER2 amplifications. Recent advancements in targeted therapy, such as HER2 inhibitors and KRASG12C inhibitors, offer promising avenues for personalized treatment. Immunotherapy, particularly checkpoint inhibitors, shows potential in tumors with high PD-L1 expression or tumor mutational burden. Novel strategies, including antibody-drug conjugates, synthetic lethality approaches, and Wnt/β-catenin pathway inhibitors, are reshaping the therapeutic landscape. Despite these developments, challenges such as intratumoral heterogeneity and therapy resistance persist, underscoring the need for innovative clinical trial designs and combination regimens. This review synthesizes the latest advancements in MOC therapies, highlighting opportunities for improved outcomes in this challenging malignancy.
Insights
Mucinous ovarian carcinoma (MOC) is a rare cancer with poor chemotherapy response. Targeted therapies, including HER2 and KRAS inhibitors, alongside immunotherapy, offer new treatment avenues for this challenging malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer subtype.
- MOC exhibits resistance to conventional platinum-based chemotherapy.
- Distinct molecular features include frequent KRAS mutations and HER2 amplifications.
Purpose of the Study:
- To review recent advancements in therapeutic strategies for MOC.
- To highlight emerging targeted therapies and immunotherapies.
- To discuss challenges and future directions in MOC treatment.
Main Methods:
- Literature review of recent studies on MOC therapies.
- Analysis of targeted therapy efficacy (HER2, KRAS inhibitors).
- Evaluation of immunotherapy potential (checkpoint inhibitors).
Main Results:
- Targeted therapies like HER2 and KRAS inhibitors show promise.
- Immunotherapy may benefit MOC with high PD-L1 or tumor mutational burden.
- Novel approaches include antibody-drug conjugates and pathway inhibitors.
Conclusions:
- Personalized treatment strategies are emerging for MOC.
- Overcoming intratumoral heterogeneity and resistance is crucial.
- Innovative clinical trials and combination regimens are needed for improved outcomes.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
08:55Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
